Nexvax2® is a vaccine that is designed to restore coeliac patients' immune tolerance to gluten. The drug is currently undergoing clinical trial as part of its development by ImmusanT, a privately-held biotechnology company. ImmusanT has recently released a report summarizing recent review articles that describe advances made in designing immunotherapies and new methods for monitoring celiac disease as well as other autoimmune disorders such as Type 1 diabetes.
In addition to contributing papers in the journals 'Current Opinion in Immunology' and 'Nature Reviews Immunology', ImmusanT staff and scientific advisors will also be presenting at the 15th International Celiac Disease Symposium to be hosted by the University of Chicago Celiac Disease Center, September 22 -25, 2013. The meeting is said to bring together the world's top scientists and physicians to discuss the most recent scientific advances in managing and treating coeliac disease and gluten-related disorders.
The summary of research advances, and links to the recent publications by the ImmusanT team, plus further details on the forthcoming Symposium can be found on the ImmusanT website.